Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IB-01
- Development stage
- Unknown
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
IB-01, also known as 多肽蛋白免疫提升剂 (Polypeptide Protein Immune Enhancer), is a peptide/protein-based agent under clinical investigation in China for its ability to enhance immune function. The drug is being evaluated for safety and efficacy in boosting immunity, with at least one registered clinical trial (ChiCTR2400082076) focused on its application for immune enhancement. The product appears to be designed as an immunomodulator, likely leveraging the properties of peptides and proteins to stimulate or regulate components of the immune system. Specific molecular targets or detailed mechanisms have not been disclosed in public sources; however, such agents typically act by promoting activation or proliferation of immune cells or by modulating cytokine production[1][2].
- Other names
- 多肽蛋白免疫提升剂
Beyond the preview
Go deeper on IB-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IB-01.